DescriptionThe Recombinant SARS-CoV Nucleocapsid Protein is manufactured with N-terminal fusion HisTag. The Recombinant SARS-CoV Nucleocapsid His-Tagged Fusion Proteinis 47.8 kDa containing 422 amino acid residues of the SARS-CoV Nucleocapsid protein
Warning: Last items in stock!
Availability date:
SARS-CoV Nucleocapsid ( 422a.a ) Recombinant ( SARS-CoV )
DescriptionThe Recombinant SARS-CoV Nucleocapsid Protein is manufactured with N-terminal fusion HisTag. The Recombinant SARS-CoV Nucleocapsid His-Tagged Fusion Proteinis 47.8 kDa containing 422 amino acid residues of the SARS-CoV Nucleocapsid protein
Recipient :
* Required fields
or Cancel
Storage | Store lyophilized protein at -20°C. Aliquot the product after reconstitution to avoid repeated freezing/thawing cycles. Reconstituted protein can be stored at 4°C for a limited period of time; it does not show any change after two weeks at 4°C. |
Formulation | Sterile filtered and lyophilized from 0.5 mg/ml in 0.05M Acetate buffer pH4. |
Solubility | Add 0.2 ml of 0.1M Acetate buffer pH4 and let the lyophilized pellet dissolve completely. For conversion into higher pH value, we recommend intensive dilution by relevant buffer to a concentration of 10g/ml. In higher concentrations the solubility of this antigen is limited. |
Purity | Greater than 95% as determined by SDS-PAGE. |
Applications | Western blotting. |
Description | The Recombinant SARS-CoV Nucleocapsid Protein is manufactured with N-terminal fusion HisTag. The Recombinant SARS-CoV Nucleocapsid His-Tagged Fusion Proteinis 47.8 kDa containing 422 amino acid residues of the SARS-CoV Nucleocapsid protein and 15 additional amino acid residues HisTag (underlined). |
Protein Background | SARS Coronavirus is an enveloped virus containing three outer structural proteins, namely the membrane (M), envelope (E), and spike (S) proteins. Spike (S)-glycoprotein of the virus interacts with a cellular receptor and mediates membrane fusion to allow viral entry into susceptible target cells. Accordingly, S-protein plays an important role in virus infection cycle and is the primary target of neutralizing antibodies. |
Expression host | Escherichia coli. |
Amino acid sequence | MRGSHHHHHH GMASHMSDNG PQSNQRSAPR ITFGGPTDST DNNQNGGRNG ARPKQRRPQG LPNNTASWFT ALTQHGKEEL RFPRGQGVPI NTNSGPDDQI GYYRRATRRV RGGDGKMKEL SPRWYFYYLG TGPEASLPYG ANKEGIVWVA TEGALNTPKD HIGTRNPNNN AATVLQLPQG TTLPKGFYAE GSRGGSQASS RSSSRSRGNS RNSTPGSSRG NSPARMASGG GETALALLLL DRLNQLESKV SGKGQQQQGQ TVTKKSAAEA SKKPRQKRTA TKQYNVTQAF GRRGPEQTQG NFGDQDLIRQ GTDYKHWPQI AQFAPSASAF FGMSRIGMEV TPSGTWLTYH GAIKLDDKDP QFKDNVILLN KHIDAYKTFP PTEPKKDKKK KTDEAQPLPQ RQKKQPTVTL LPAADMDDFS RQLQNSMSGA SADSTQA. |
Purification Method | Three-step procedure using affinity Ni-NTA chromatography and size exclusion chromatography before and after refolding. |